Abstract
| Original language | English |
|---|---|
| Article number | 807 |
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Biomedicines |
| Volume | 11 |
| Issue number | 3 |
| Early online date | 7 Mar 2023 |
| DOIs | |
| Publication status | Published online - 7 Mar 2023 |
Bibliographical note
Funding Information:This work was supported by grants from Berth von Kantzow’s Foundation, ERC-2018-AdG 834860 EYELETS, the Family Erling-Persson Foundation, Funds at Karolinska Institutet, the Stichting af Jochnick Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the Swedish Alzheimer Association, the Swedish Diabetes Association, the Swedish Foundation for Strategic Research, the Swedish Research Council and the Novo Nordisk Foundation. R.M.S. has been supported by NIH (NIDDK) SBIR grants (2R44DKI 04497-02, 1R43DKl04497-01, 1R43DK108441-01Al, 1R43DK112472-01, 5R44DK104497-03 and 1 R43DK109832-01A1).
Funding Information:
P.-O.B. is the founder and CEO of the biotech company BioCrine AB. M.K. and S.-N.Y. are consultants to BioCrine. A.K. and J.O. are co-founders of Regenerative Medical Solutions, Inc. and have equity interest in the company. The research reported here was supported in part by funding provided by Regenerative Medical Solutions, Inc. A.M. and T.J. are employees of Regenerative Medical Solutions, Inc.
Publisher Copyright:
© 2023 by the authors.
Funding
Funding Information: This work was supported by grants from Berth von Kantzow’s Foundation, ERC-2018-AdG 834860 EYELETS, the Family Erling-Persson Foundation, Funds at Karolinska Institutet, the Stichting af Jochnick Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the Swedish Alzheimer Association, the Swedish Diabetes Association, the Swedish Foundation for Strategic Research, the Swedish Research Council and the Novo Nordisk Foundation. R.M.S. has been supported by NIH (NIDDK) SBIR grants (2R44DKI 04497-02, 1R43DKl04497-01, 1R43DK108441-01Al, 1R43DK112472-01, 5R44DK104497-03 and 1 R43DK109832-01A1). Funding Information: P.-O.B. is the founder and CEO of the biotech company BioCrine AB. M.K. and S.-N.Y. are consultants to BioCrine. A.K. and J.O. are co-founders of Regenerative Medical Solutions, Inc. and have equity interest in the company. The research reported here was supported in part by funding provided by Regenerative Medical Solutions, Inc. A.M. and T.J. are employees of Regenerative Medical Solutions, Inc. Publisher Copyright: © 2023 by the authors.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- anterior chamber of the eye (ACE)
- calcium channel
- cytoplasmic-free Ca2+ concentration ([Ca2+]i)
- stem cell
- in vivo confocal microscopy
- islet
- cytoplasmic-free Ca concentration ([Ca ] )
Fingerprint
Dive into the research topics of 'In Vivo CaV3 Channel Inhibition Promotes Maturation of Glucose-Dependent Ca2+ Signaling in Human iPSC-Islets'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver